Read Time: 7 mins

Diabetes and Stem Cells—A 10-year Perspective

Copy Link
Published Online: Nov 7th 2011 US Endocrinology, 2007;(2):23-5 DOI:
Authors: Juan Dom
Quick Links:
Article Information

We are approaching the 10th anniversary of the isolation of human embryonic stem (huES) cells,1 a seminal breakthrough that promptly germinated into one of the most prolific fields in recent scientific history. Concepts such as ‘regenerative medicine’ or ‘stem cell therapies,’ so commonly used today, did not start to appear in the scientific literature until the late 1990s.

We are approaching the 10th anniversary of the isolation of human embryonic stem (huES) cells,1 a seminal breakthrough that promptly germinated into one of the most prolific fields in recent scientific history. Concepts such as ‘regenerative medicine’ or ‘stem cell therapies,’ so commonly used today, did not start to appear in the scientific literature until the late 1990s. Although stem cell transplantation had been in clinical use for several decades for bloodrelated disorders, the notion that totally plastic, indefinitely expandable cells could be used as building blocks for the in vitro regeneration of any tissue was nothing less than revolutionary. Until then, and despite reports of ES cells obtained from many species,2–4 it is as though we had not envisioned applications for these singular cells other than to create animal models for human diseases, increase livestock output, or improve the production of therapeutic proteins from transgenic animals. The feeling of unexpectedness that saluted the birth of this new field is reflected in the fact that 1998 marked the starting point not only of huES cell research, but also of a sudden interest in adult stem cells as an alternative source of tissues. After all, the procurement of ES cells from human and non-human primates had been hampered by technical difficulties up to that point, but the technology necessary to expand most adult stem cells was already in use a decade ago. Why had we not been pursuing the idea of using adult stem cells for medical purposes until Thomson and colleagues came up with the first embryonic stem cell lines? Be that as it may, a new field was born as the result of the confluence of disciplines as diverse as embryology, immunology, cell biology, and transplantation surgery.

Ten years later, the promise of this new field is evidenced by the use of several types of adult stem cells in clinical trials for a variety of conditions, including Crohn’s disease,5 myocardial infarction,6 and graft-versus-host disease.7,8 New applications of autologous bone marrow transplantation are currently being developed either to tackle autoimmunity9–11 or to induce regeneration in diseases such as diabetes.12 Since they are still experimental, it is too early to determine whether or not these therapies will eventually change the state of the art in treating these conditions. Also (in what represents a reversion of the usual ‘bench to bedside’ directionality), once these therapies prove safe and effective, we must investigate the mechanisms behind the potential action of the transplanted cells. Do they work by differentiating into the types of cells that were damaged, or—as suggested by preliminary evidence—merely by flooding the damaged tissues with trophic signals that aid in self-regeneration? We can afford to answer these questions after the trials because, in the context of their proposed applications, most adult stem cells are relatively safe. This course of action is not possible with huES cells, and this is the only reason why they seem to lag behind their adult counterparts in terms of clinical applicability. The very same property that makes huES cells superior to other stem cells (i.e. their ability to be expanded indefinitely) is also a cause of concern because of the risk that some non-differentiated escapees may give rise to teratomas in vivo. Some groups have approached this problem by screening the number of undifferentiated cells present in each transplantable preparation. Their reasoning is that, if this number is below the threshold known to produce tumors in immunodeficient mice, these preparations should be considered safe for clinical use.13 This method, however, is not foolproof. First, not even the best cell-sorting techniques can ensure a 100% depletion of a rare subset of cells in a population. Second, the above threshold has been determined empirically. In theory, even a single non-differentiated cell could potentially develop into a tumor. Finally, it does not take into account the risk of de-differentiation after transplantation.14 This is why other groups have addressed this problem by integrating ‘suicide genes’ into ES cells. These elements sensitize ES cells to specific pro-drugs, which can be either added to the culture medium in vitro or administered to the recipient in vivo. The proteins encoded by these exogenous genes will react with the pro-drug and convert it into a toxic compound, which will subsequently kill the cell.15–19 A drawback of this strategy is that if teratomas were to form in vivo due to de-differentiation of implanted cells, the use of the pro-drug would result in the destruction of the entire graft (see Figure 1). At any rate, the escape of undifferentiated cells is only one of the ways in which an embryonic stem cell may become teratogenic. Less attention has been paid to a much subtler risk: the accumulation of genomic instabilities as a result of long-term culture. Initial reports about the karyotypic stability of huES cells1,20–22 have been recently revisited in view of the observation that the adaptation of these cells to prolonged in vitro culture does indeed favor the development of chromosomal aberrations.23 The unequivocal similitude between in vitro proliferative adaptation and malignant transformation24 warrants additional studies to assess the overall safety of huES cell-based therapies.
In view of the above, it is understandable that clinical trials with huES cells have been approached with much more caution than those based on the use of adult stem cells. If everything proceeds according to schedule, these first trials will take place before the end of 2007, and will look at the efficacy of huES cell-derived oligodendrocytes to treat acute spinal cord injuries. A positive result will definitely help to soften the opposition of a still significant sector of the population to huES cell research. By the same token, a negative outcome would be likely to set the entire field back, perhaps irreversibly. Social pressure to develop cures, fueled by some unrealistic promises about the time-frame and scope of these treatments, should not stand in the way of their cautious planning and implementation. The lessons that we have learned from failed gene therapy trials must remain fresh in our memory.

Despite obvious advances in this field, the experimental challenges remain the same they were a decade ago. The most important one is the inability to mimic in vitro the intricate biochemical regulation of in vivo development. Insulinproducing β cells, which are the main subject of our review, are a perfect example of these limitations. These cells are destroyed by the immune system in type I diabetes, and therefore are prime candidates for cell replacement therapies. As islet transplantation from deceased donors was demonstrated to be safe and efficacious,25,26 proof of principle was established that huES cellderived β cells could be used to effectively treat the disease. Decades of progress in the identification of the main molecular determinants of pancreatic specification gave shape to the idea that this process could be reproduced in vitro by simply providing huES cells with the appropriate combination of extracellular signals. This has proven to be much more difficult than anticipated. Throughout pancreatic development, cells respond differentially to extracellular cues depending on their precise location, their interaction with surrounding tissues, and time. Fine gradients of Nodal (for endoderm/gut endothelium specification), FGF and Shh (for pancreatic differentiation), and direct cell-to-cell interactions in the Notch pathway (for endocrine specification), are examples of the complex differentiation mechanisms that we are only now beginning to understand. The biochemical environment is just one of the levels of complexity with which in vitro differentiation protocols have to deal. Increasing lines of evidence point to physical variables as important determinants of development/cell specification. Among these, some of the most studied are mechanical forces,27,28 pH and bioelectrical fields,2,9–31 oxygenation levels,32–35 and the nature of the substrate/mode of culture.36–39 The metabolic activity of the adult islet is highly dependent on the complex network of blood vessels that pervades it. In fact, although islets account for only 1–2% of the total number of cells of the pancreas, they use 25% of the pancreatic O2 supply.40,41 When removed from their in vivo environment, the islet microvascular network is destroyed and viability decreases dramatically.42 In short, standard culture practice is not favorable for long-term islet survival and function.42 How can we generate islets from stem cells if the physical conditions for islets to survive in the first place have not been optimized yet? The very same limitations that result in β-cell death in vitro may also prevent their efficient differentiation from immature progenitors.

In summary, 10 years of research has led us to the humbling realization that mimicking pancreatic development in vitro is a much more formidable enterprise than previously thought. Today, even the best protocols for directed huES cell differentiation yield only a small percentage of β cells,43 which in some cases are not even glucose-responsive44 (see Figure 2). New trends to address this problem illustrate the need for interdisciplinary approaches in order to succeed at translating basic research into clinical therapies. One example is the cross-pollination between biology and physical sciences, which has led to the development of an entirely new discipline called tissue engineering. The notion that physical and molecular microenvironments are equally important in the evolution of pancreatic development is still a relatively new one, at least in the context of in vitro differentiation. We have shown, for instance, that molecular oxygen is a critical determinant of β-cell differentiation.45 The design of novel culture devices to improve oxygen delivery (thus enhancing differentiation of stem cells into insulin-producing cells) is one example of the fruitful crosspollination between molecular biology and biophysical disciplines (see Figure 3). As the molecular environment is only one part of the equation of islet differentiation, replacement is just the most visible facet of any future cure for type I diabetes. There is widespread consensus that the re-education of the immune system must be an essential component of any therapeutic approach. Even in a best-case scenario where the exogenously provided β cells were autologous (through therapeutic cloning or from adult stem cells obtained from the patient), this approach would be insufficient to prevent the recurrence of autoimmunity. In fact, there is evidence suggesting that the body attempts to regenerate its β-cell mass for decades after the diagnosis of the disease, but auto-reactive processes keep targeting these new cells as they appear.46 On the other hand, immunological interventions alone might not be sufficient to completely restore β-cell function. A recent study designed to ‘reset the clock’ of the immune system to a point prior to the onset of the disease was partially successful in recently diagnosed patients, but did not work in individuals with long-standing diabetes.11 This would be consistent with the hypothesis that the body cannot regenerate a functional β-cell mass after a threshold of destruction, a point of no return beyond which re-education of the immune system would have to be supplemented with a boost of exogenous β cells.

Despite what might be perceived as a slow pace in translating basic findings into effective therapies for type I diabetes, the last decade has been enormously productive in terms of framing the problem and shaping the overall direction of the field. Indeed, progress along this line of research has been steadfast, and the current state of the art suggests that huES cell-based trials, perhaps combined with immunological therapies, might be around the corner. As type I diabetes is a complex disease, it is reasonable to expect that a cure will come only from a multidisciplinary effort, which will almost certainly include a strong stem cell component.■

JDB research is funded by the Diabetes Research Institute Foundation, the American Diabetes Association, the Juvenile Diabetes Research Foundation, and the Wallace H Coulter Foundation.


  1. Thomson J A, et al., Embryonic stem cell lines derived from human blastocysts, Science, 1998;282(5391):1145–7.
  2. Evans M J, Kaufman MH, Establishment in culture of pluripotential cells from mouse embryos, Nature, 1981;292(5819):154–6.
  3. Martin GR, Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells, Proc Natl Acad Sci U S A, 1981;78(12):7634–8.
  4. Wilmut I, Whitelaw CB, Strategies for production of pharmaceutical proteins in milk, Reprod Fertil Dev, 1994;6(5):625–30.
  5. Garcia-Olmo D, et al., A phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation, Dis Colon Rectum, 2005;48(7):1416–23.
  6. Hare J, A Double-Blind, Randomized, Placebo Controlled Clinical Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Patients With Acute Myocardial Infarction, Innovation in Intervention: i2 Summit, 2007, New Orleans: American College of Cardiology.
  7. Fang B, et al., Treatment of severe therapy-resistant acute graftversus- host disease with human adipose tissue-derived mesenchymal stem cells, Bone Marrow Transplant, 2006;38(5):389–90.
  8. Ringden O, et al., Mesenchymal stem cells for treatment of therapyresistant graft-versus-host disease, Transplantation, 2006;81(10): 1390–97.
  9. Burt RK, et al., Hematopoietic stem cell transplantation for multiple sclerosis, Arch Neurol, 2005;62(6):860–64.
  10. Burt RK, et al., Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens, Arthritis Rheum, 2006;54(12):3750–60.
  11. Voltarelli JC, et al., Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus, JAMA, 2007;297(14):1568–76.
  12. Fernández-Viña R, Saslavsky J, Camozzi L, et al., Direct pancreas implant by selective catheterization of spleen artery of autologous adult mononuclear CD34+/CD38- cells to increase insulin and Cpeptide in type I diabetic patients, Spring 2007 meeting of the Genetics Society, the British Society for Developmental Biology and the British Society of Cell Biology, 2007, Heriot-Watt University, Edinburgh.
  13. Vogel G, Cell biology. Ready or not? Human ES cells head toward the clinic, Science, 2005;308(5728):1534–8.
  14. Fujikawa T, et al., Teratoma formation leads to failure of treatment for type I diabetes using embryonic stem cell-derived insulinproducing cells, Am J Pathol, 2005;166(6):1781–91.
  15. Tamada K,Wang XP, Brunicardi FC, Molecular targeting of pancreatic disorders, World J Surg, 2005;29(3):325–33.
  16. Wang XP, et al., Specific gene expression and therapy for pancreatic cancer using the cytosine deaminase gene directed by the rat insulin promoter, J Gastrointest Surg, 2004;8(1):98–108; discussion 106–8.
  17. Yazawa K, Fisher WE, Brunicardi FC, Current progress in suicide. Gene therapy for cancer, World J Surg, 2002;26(7):783–9.
  18. Schuldiner M, Itskovitz-Eldor J, Benvenisty N, Selective ablation of human embryonic stem cells expressing a “suicide” gene, Stem Cells, 2003;21(3):257–65.
  19. Fareed MU, Moolten FL, Suicide gene transduction sensitizes murine embryonic and human mesenchymal stem cells to ablation on demand—a fail-safe protection against cellular misbehavior, Gene Ther, 2002;9(14):955–62.
  20. Amit M, et al., Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture, Dev Biol, 2000;227(2):271–8.
  21. Rosler ES, et al., Long-term culture of human embryonic stem cells in feeder-free conditions, Dev Dyn, 2004;229(2):259–74.
  22. Carpenter MK, Rosler E, Rao MS, Characterization and differentiation of human embryonic stem cells, Cloning Stem Cells, 2003;5(1):79–88.
  23. Imreh MP, et al., In vitro culture conditions favoring selection of chromosomal abnormalities in human ES cells, J Cell Biochem, 2006;99(2):508–16.
  24. Baker DE, et al., Adaptation to culture of human embryonic stem cells and oncogenesis in vivo, Nat Biotechnol, 2007;25(2):207–15.
  25. Ricordi C. and T.B. Strom, Clinical islet transplantation: advances and immunological challenges, Nat Rev Immunol, 2004;4(4):259–68.
  26. Poggioli R, et al., Quality of life after islet transplantation, Am J Transplant, 2006;6(2):371–8.
  27. Chen C, Using microenvironment to engineer stem cell function, Conf Proc IEEE Eng Med Biol Soc, 2004;7:4964.
  28. Nelson CM, et al., Emergent patterns of growth controlled by multicellular form and mechanics. Proc Natl Acad Sci U S A, 2005;102(33):11594–9.
  29. Levin M, Bioelectromagnetics in morphogenesis, Bioelectromagnetics, 2003;24(5):295–315.
  30. Robinson KR, Messerli MA, Left/right, up/down: the role of endogenous electrical fields as directional signals in development, repair and invasion, Bioessays, 2003;25(8):759–66.
  31. Nuccitelli R, Ionic currents in morphogenesis, Experientia, 1988;44(8):657–66.
  32. Diez H., et al., Hypoxia-mediated activation of Dll4-Notch-Hey2 signaling in endothelial progenitor cells and adoption of arterial cell fate. Exp Cell Res, 2007;313(1):1–9.
  33. D’Ippolito G, et al., Low oxygen tension inhibits osteogenic differentiation and enhances stemness of human MIAMI cells, Bone, 2006;39(3):513–22.
  34. Grayson WL, et al., Effects of hypoxia on human mesenchymal stem cell expansion and plasticity in 3D constructs, J Cell Physiol, 2006;207(2):331–9.
  35. Gustafsson MV, et al., Hypoxia requires notch signaling to maintain the undifferentiated cell state, Dev Cell, 2005;9(5):617–28.
  36. Czyz J,Wobus A, Embryonic stem cell differentiation: the role of extracellular factors, Differentiation, 2001;68(4–5):167–74.
  37. Li WJ, Jiang YW, Tuan RS, Chondrocyte phenotype in engineered fibrous matrix is regulated by fiber size, Tissue Eng, 2006;12(7):1775–85.
  38. Liu H, Collins SF, Suggs LJ, Three-dimensional culture for expansion and differentiation of mouse embryonic stem cells, Biomaterials, 2006;27(36):6004–14.
  39. Liu H, J Lin, Roy K, Effect of 3D scaffold and dynamic culture condition on the global gene expression profile of mouse embryonic stem cells, Biomaterials, 2006;27(36):5978–89.
  40. Lifson N, et al., Blood flow to the rabbit pancreas with special reference to the islets of Langerhans, Gastroenterology, 1980;79(3):466–73.
  41. Jansson L, The regulation of pancreatic islet blood flow, Diabetes Metab Rev, 1994;10(4):407–16.
  42. Giuliani M, et al., Central necrosis in isolated hypoxic human pancreatic islets: evidence for postisolation ischemia, Cell Transplant, 2005;14(1):67–76.
  43. Jiang J, et al., Generation of Insulin-producing Islet-like Clusters from Human Embryonic Stem Cells, Stem Cells, 2007.
  44. D’Amour KA, et al., Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells, Nat Biotechnol, 2006.
  45. Fraker CA, et al., Enhanced oxygenation promotes beta cell differentiation in vitro, Stem Cells, 2007.
  46. Meier JJ, et al., Sustained beta cell apoptosis in patients with longstanding type 1 diabetes: indirect evidence for islet regeneration?, Diabetologia, 2005;48(11):2221–8.

Further Resources

Share this Article
Related Content In Diabetes
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72